Related Experiment Video

Updated: Jul 17, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Current topics in melanoma

Jedd D Wolchok1, Yvonne M Saenger

  • 1Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. wolchokj@mskcc.org

Current Opinion in Oncology
|February 3, 2007
PubMed
Abstract

Insights

Advances in melanoma treatment include new standards for surgical care and promising immunotherapies like anti-CTLA-4. Research into melanoma genetics and immune regulation is driving novel targeted therapies.

Area of Science:

  • Dermatology
  • Oncology
  • Immunology

Background:

  • Melanoma treatment is rapidly evolving with new therapeutic strategies.
  • Understanding melanoma genetics and immune regulation is crucial for progress.

Purpose of the Study:

  • To review recent advancements in melanoma treatment over the past 12 months.
  • To summarize emerging surgical, chemotherapeutic, immunologic, and targeted therapies.

Main Methods:

  • Literature review of developments in melanoma research and clinical practice.
  • Analysis of recent evidence on therapeutic efficacy and safety.

Main Results:

  • Sentinel lymph node sampling is now standard for intermediate-thickness melanomas.
  • Combination therapy with temozolomide and interferon-alpha shows potential superiority.
  • Anti-CTLA-4 immunotherapy shows promise but requires monitoring for toxicity.
  • Neoadjuvant interferon-alpha demonstrates efficacy with inflammatory responses.
  • Emerging understanding of melanoma genetics is paving the way for targeted therapies.

Conclusions:

  • Research is deepening the understanding of melanoma genetics and immune responses.
  • New therapeutics are emerging and beginning to impact clinical practice for melanoma patients.

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Related Concept Videos

Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Changes in Skin Color: Clinical Perspectives01:14

Changes in Skin Color: Clinical Perspectives

The first thing a clinician sees is the skin, so the examination of the skin should be part of any thorough physical examination. Most skin disorders are relatively benign, but a few, including melanomas, can be fatal if untreated. A couple of the more noticeable disorders, albinism and vitiligo, affect the appearance of the skin and its accessory organs.
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...